A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation

  • Michael Uhlin
  • Mantas Okas
  • Jens Gertow
  • Mehmet Uzunel
  • Torkel B. Brismar
  • Jonas Mattsson
Short Communication

Abstract

Epstein–Barr virus (EBV)-related malignancies such as post-transplant lymphoproliferative disease (PTLD) are severe complications after allogeneic stem cell transplantation and solid-organ transplantation. In immunosuppressed transplant recipients, the activity of EBV-specific CTLs are often decreased or absent which leads to an increased risk of developing PTLD. If primary treatment modalities of PTLD fail, the most efficient way of treating the malignancy is adopting EBV-specific CTLs from the donor or, more recently, third-party donors. However, both are time consuming and expensive and often it is too late to administer cells to the patient. We have for the first time, using a rapid isolation protocol of EBV-specific T cells, treated and cured a patient suffering from PTLD with multiple-associated tissue lesions, using her haplo-identical mother as a donor. This treatment approach paves way for a new possibility to within-days treat patients with life-threatening EBV-associated malignancies.

Keywords

EBV lymphoma T cells Adoptive transfer Pentamer 

References

  1. 1.
    Hou HA, Yao M, Tang JL, Chen YK, Ko BS, Huang SY, Tien HF, Chang HH, Lu MY, Lin TT, Lin KH, Hsiao CH, Lin CW, Chen YC (2009) Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years’ experience in a single institute. Bone Marrow Transplant 43(4):315–321CrossRefPubMedGoogle Scholar
  2. 2.
    Sundin M, Le Blanc K, Ringden O, Barkholt L, Omazic B, Lergin C, Levitsky V, Remberger M (2006) The role of HLA mismatch, splenectomy and recipient Epstein–Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica 91(8):1059–1067PubMedGoogle Scholar
  3. 3.
    Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB (1992) Identification of target antigens for the human cytotoxic T cell response to Epstein–Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 176(1):157–168CrossRefPubMedGoogle Scholar
  4. 4.
    Khatri VP, Baiocchi RA, Peng R, Oberkircher AR, Dolce JM, Ward PM, Herzig GP, Caligiuri MA (1999) Endogenous CD8+ T cell expansion during regression of monoclonal EBV-associated posttransplant lymphoproliferative disorder. J Immunol 163(1):500–506PubMedGoogle Scholar
  5. 5.
    Brunstein CG, Weisdorf DJ, DeFor T, Barker JN, Tolar J, van Burik JA, Wagner JE (2006) Marked increased risk of Epstein–Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 108(8):2874–2880CrossRefPubMedGoogle Scholar
  6. 6.
    Davis JE, Moss DJ (2004) Treatment options for post-transplant lymphoproliferative disorder and other Epstein–Barr virus-associated malignancies. Tissue Antigens 63(4):285–292CrossRefPubMedGoogle Scholar
  7. 7.
    Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P, Ringden O, Winiarski J, Ernberg I, Masucci MG (2000) Epstein–Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 95(3):807–814PubMedGoogle Scholar
  8. 8.
    Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, Srivastava DK, Bowman LC, Krance RA, Brenner MK, Heslop HE (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92(5):1549–1555PubMedGoogle Scholar
  9. 9.
    Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H, Assenmacher M, Billingham L, Steward C, Crawley C, Olavarria E, Goldman J, Chakraverty R, Mahendra P, Craddock C, Moss PA (2005) Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 202(3):379–386CrossRefPubMedGoogle Scholar
  10. 10.
    Hancock JP, Goulden NJ, Oakhill A, Steward CG (2003) Quantitative analysis of chimerism after allogeneic bone marrow transplantation using immunomagnetic selection and fluorescent microsatellite PCR. Leukemia 17(1):247–251CrossRefPubMedGoogle Scholar
  11. 11.
    Hong GK, Gulley ML, Feng WH, Delecluse HJ, Holley-Guthrie E, Kenney SC (2005) Epstein–Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J Virol 79(22):13993–14003CrossRefPubMedGoogle Scholar
  12. 12.
    Adhikary D, Behrends U, Moosmann A, Witter K, Bornkamm GW, Mautner J (2006) Control of Epstein–Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med 203(4):995–1006CrossRefPubMedGoogle Scholar
  13. 13.
    Adhikary D, Behrends U, Boerschmann H, Pfunder A, Burdach S, Moosmann A, Witter K, Bornkamm GW, Mautner J (2007) Immunodominance of lytic cycle antigens in epstein-barr virus-specific CD4+ T cell preparations for therapy. PLoS One 2(7):e583CrossRefPubMedGoogle Scholar
  14. 14.
    Hong GK, Kumar P, Wang L, Damania B, Gulley ML, Delecluse HJ, Polverini PJ, Kenney SC (2005) Epstein–Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. J Virol 79(22):13984–13992CrossRefPubMedGoogle Scholar
  15. 15.
    De Geer A, Kiessling R, Levitsky V, Levitskaya J (2006) Cytotoxic T lymphocytes induce caspase-dependent and -independent cell death in neuroblastomas in a MHC-nonrestricted fashion. J Immunol 177(11):7540–7550PubMedGoogle Scholar
  16. 16.
    Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P, Burns D, McAulay K, Turner M, Bellamy C, Amlot PL, Kelly D, MacGilchrist A, Gandhi MK, Swerdlow AJ, Crawford DH (2007) Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110(4):1123–1131CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Michael Uhlin
    • 1
  • Mantas Okas
    • 1
  • Jens Gertow
    • 1
  • Mehmet Uzunel
    • 1
  • Torkel B. Brismar
    • 2
  • Jonas Mattsson
    • 1
  1. 1.Division of Clinical Immunology, Centre for Allogeneic Stem Cell TransplantationKarolinska University Hospital HuddingeStockholmSweden
  2. 2.CLINTEC, Department of RadiologyKarolinska University Hospital HuddingeStockholmSweden

Personalised recommendations